MRK vs POCI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
POCI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows impressive top-line revenue growth of 62.80%, this growth is not translating into profitability, as evidenced by a -28.33% profit margin and a catastrophic -73.56% ROE. Liquidity is tight with a Quick Ratio of 0.58, and the company has failed to beat earnings estimates in the last four quarters. The recent short-term price rally appears decoupled from the underlying financial deterioration.
Compare Another Pair
Related Comparisons
MRK vs POCI: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Precision Optics Corporation, Inc. (POCI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.